SCHEMBL1643502

SCHEMBL1643502

OCC1CC(O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9020016 1.00
SCHEMBL18849923 0.97 EPHX2 (0.44)
SCHEMBL19663557 0.97 EPHX2 (0.44)
SCHEMBL14621075 0.97 EPHX2 (0.39)
SCHEMBL23717800 0.84 EPHX2 (0.32)
SCHEMBL12442307 0.84 EPHX2 (0.58)
SCHEMBL7942810 0.84 EPHX2 (0.58)
SCHEMBL13921587 0.84 EPHX2 (0.58)
SCHEMBL10066213 0.84 EPHX2 (0.37)
SCHEMBL6459361 0.82 CYP2C9 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4702022-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE Halda Therapeutics Opco, Inc. (US) 2026-03-04 EP disclosed
US-20260028338-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO INC (US) 2026-01-29 US disclosed
US-20250270190-A1 KIT INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-08-28 US disclosed
EP-4572755-A2 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-06-25 EP disclosed
EP-4568946-A1 MACROCYCLIC BCL6 DEGRADERS Dana-Farber Cancer Institute, Inc. (US) 2025-06-18 EP disclosed
EP-4561999-A1 TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY Abbvie Operations Singapore Pte. Ltd. (SG) 2025-06-04 EP disclosed
CN-116648248-B Aromatic compound, pharmaceutical composition containing same and application thereof 成都茵创园医药科技有限公司 2025-04-15 CN disclosed
CN-119585240-A Macrocyclic BCL6 degrading agents 丹娜-法伯癌症研究院 2025-03-07 CN disclosed
WO-2025022124-A2 METHODS FOR DEPOLYMERISING AND REPOLYMERISING Epoch Biodesign Ltd (GB) 2025-01-30 WO disclosed
WO-2024217515-A1 HETEROCYCLIC RING-SUBSTITUTED AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海复宏汉霖生物技术股份有限公司 2024-10-24 WO disclosed
CN-1040426-C Process for preparing diprotected 2,3-hydroxymethyl cyclobutanol SQUIBB & SONS INC (US) 1998-10-28 CN disclosed
CN-1036712-C Process for preparing guanine-containing antiviral agents and purinyl salts useful in such process SQUIBB & SONS INC (US) 1997-12-17 CN disclosed
EP-0352013-B1 Hydroxymethyl cyclobutyl purines SQUIBB & SONS INC (US) 1996-05-01 EP disclosed
US-5369098-A Viricides E. R. SQUIBB & SONS, INC. (US) 1994-11-29 US disclosed
CN-1083813-A Contain guanine antiviral agent the preparation method and be used for the purine salt of this method SQUIBB & SONS INC (US) 1994-03-16 CN disclosed
CN-1082025-A 2 of two protections, the preparation method of 3-methylol cyclobutanol SQUIBB & SONS INC (US) 1994-02-16 CN disclosed
CN-1082025-A 2 of two protections, the preparation method of 3-methylol cyclobutanol SQUIBB & SONS INC (US) 1994-02-16 CN disclosed
EP-0352013-A2 Hydroxymethyl cyclobutyl purines E.R. Squibb &amp; Sons, Inc. (US) 1990-01-24 EP disclosed
EP-0330992-A2 Novel cyclobutane Derivatives, processes for their preparation and pharmaceutical compositions comprising them Nippon Kayaku Kabushiki Kaisha (JP) 1989-09-06 EP disclosed
US-4096129-A Glutarate-containing polyesterpolyols, methods of preparation and polyurethane compositions derived therefrom FABRIDYNE, INC. (US) 1978-06-20 US disclosed